329 related articles for article (PubMed ID: 19429509)
1. Assessing the bioequivalence of biosimilars The Retacrit case.
Schellekens H
Drug Discov Today; 2009 May; 14(9-10):495-9. PubMed ID: 19429509
[TBL] [Abstract][Full Text] [Related]
2. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
Jelkmann W
Am J Hematol; 2010 Oct; 85(10):771-80. PubMed ID: 20706990
[TBL] [Abstract][Full Text] [Related]
3. Basic facts about biosimilars.
Nowicki M
Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars: how similar or dissimilar are they?
Roger SD
Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
[TBL] [Abstract][Full Text] [Related]
5. Non-clinical safety studies on biosimilar recombinant human erythropoietin.
Parnham MJ; Schindler-Horvat J; Kozlović M
Basic Clin Pharmacol Toxicol; 2007 Feb; 100(2):73-83. PubMed ID: 17244255
[TBL] [Abstract][Full Text] [Related]
6. The first biosimilar epoetin: but how similar is it?
Schellekens H
Clin J Am Soc Nephrol; 2008 Jan; 3(1):174-8. PubMed ID: 18057303
[No Abstract] [Full Text] [Related]
7. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
Brodniewicz-Proba T
Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars: it's not as simple as cost alone.
Roger SD; Goldsmith D
J Clin Pharm Ther; 2008 Oct; 33(5):459-64. PubMed ID: 18834359
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic equivalence of complex drugs.
Schellekens H; Klinger E; Mühlebach S; Brin JF; Storm G; Crommelin DJ
Regul Toxicol Pharmacol; 2011 Feb; 59(1):176-83. PubMed ID: 20951177
[TBL] [Abstract][Full Text] [Related]
10. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
[TBL] [Abstract][Full Text] [Related]
11. Follow-on biologics: challenges of the "next generation".
Schellekens H
Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars: opportunity or cause for concern?
Roger SD; Mikhail A
J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
[TBL] [Abstract][Full Text] [Related]
13. [Position statements regarding usage of biosimilars of Epoetins. Position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique].
Bouchet JL; Brunet P; Canaud B; Chanliau J; Combe C; Deray G; Houillier P; Kourilsky O; Ledneva E; Niaudet P; Ortiz JP; Pavlovic M; Ryckelynck JP; Singlas E; Verhelst D; ; ;
Nephrol Ther; 2009 Feb; 5(1):61-6. PubMed ID: 19084489
[TBL] [Abstract][Full Text] [Related]
14. Position statement regarding usage of biosimilars: position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique.
; ;
Nephrol Ther; 2006 Dec; 2(7):432-5. PubMed ID: 17185233
[No Abstract] [Full Text] [Related]
15. Biosimilar medicines--new challenges for a new class of medicine.
Fox A
J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245
[TBL] [Abstract][Full Text] [Related]
16. EMEA guidelines on biosimilars and their clinical implications.
Rossert J
Kidney Blood Press Res; 2007; 30 Suppl 1():13-7. PubMed ID: 17726338
[No Abstract] [Full Text] [Related]
17. Biosimilar drugs : concerns and opportunities.
Genazzani AA; Biggio G; Caputi AP; Del Tacca M; Drago F; Fantozzi R; Canonico PL
BioDrugs; 2007; 21(6):351-6. PubMed ID: 18020619
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.
Combe C; Tredree RL; Schellekens H
Pharmacotherapy; 2005 Jul; 25(7):954-62. PubMed ID: 16006274
[TBL] [Abstract][Full Text] [Related]
19. [Biosimilar products--cheaper version of biological drugs. New possibilities within several therapeutic fields].
Mellstedt H
Lakartidningen; 2009 Jun 3-9; 106(23):1563-6. PubMed ID: 19583014
[No Abstract] [Full Text] [Related]
20. What are biosimilars and are they important?
Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]